secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001193125-25-178950
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasca Q2 2025 net loss $33.9M; cash $386.7M; INDs cleared for two RAS drugs
----------------------------------------------------------------------------

- Net loss of $33.9M ($0.12/sh) for Q2 2025, down from $63.2M ($0.29/sh) in Q2 2024.
- Cash, equivalents, and marketable securities $386.7M as of June 30, 2025; expected to fund operations into H2 2028.
- IND cleared for pan-KRAS inhibitor ERAS-4001 (Jun 2025) and pan-RAS molecular glue ERAS-0015 (May 2025); Phase 1 trials ongoing.
- Initial Phase 1 monotherapy data for ERAS-0015 and ERAS-4001 expected in 2026.
- R&D expenses $21.2M in Q2 2025 vs $33.0M in Q2 2024, driven by lower impairment and personnel costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000119312525178950/0001193125-25-178950-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000119312525178950/eras-20250812.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-178950

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer